Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 11, pp. 3665-3682
Open Access | Times Cited: 16

Showing 16 citing articles:

The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
Veronica Mollica, Alessandro Rizzo, Andrea Marchetti, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 5039-5049
Closed Access | Times Cited: 122
Concomitant Statin Use and Survival in Patients With Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis
Yonghe Liao, Yuxuan Lin, Xinqi Ye, et al.
JCO Oncology Practice (2025)
Closed Access | Times Cited: 1
Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma
Hsiang‐Ying Lee, Po‐Hung Lin, See‐Tong Pang, et al.
Cancer Medicine (2025) Vol. 14, Iss. 1
Open Access
Unraveling the link between cholesterol and immune system in cancer: from biological mechanistic insights to clinical evidence. A narrative review
Federica Pecci, Valeria Cognigni, Giulia Claire Giudice, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104654-104654
Closed Access
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Clinical & Experimental Metastasis (2025) Vol. 42, Iss. 2
Open Access
Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience
Mimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Cancer Medicine (2025) Vol. 14, Iss. 4
Open Access
Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade
Jie Mei, Jiahui Chu, Kai Yang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 9, pp. e009327-e009327
Open Access | Times Cited: 4
Clinical evidence for the prognostic impact of metformin in cancer patients treated with immune checkpoint inhibitors
Jinhai Shen, Xinqi Ye, Hui Hou, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112243-112243
Closed Access | Times Cited: 3
Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution
Atsunari Kawashima, Yu Ishizuya, Yoshiyuki Yamamoto, et al.
International Journal of Clinical Oncology (2024) Vol. 29, Iss. 8, pp. 1096-1104
Open Access | Times Cited: 2
Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab
Takanori Sekito, Kensuke Bekku, Satoshi Katayama, et al.
Clinical Genitourinary Cancer (2024) Vol. 22, Iss. 4, pp. 102097-102097
Closed Access | Times Cited: 1
Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer
Merissa Coleman, Sophia J. Mascialino, Anusha Panjwani, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access
Clinical implications of the Drug-Drug interaction in cancer patients treated with innovative oncological treatments
Fiorenza Santamaria, Michela Roberto, Dorelsa Buccilli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 200, pp. 104405-104405
Closed Access
No difference in oncological outcomes and perioperative complications between patients with ESRD with unilateral and bilateral UTUC receiving radical nephroureterectomy
Tsu-Chen Lin, Guan-Heng Chen, Chin-Chung Yeh, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Targeted Oncology (2024) Vol. 19, Iss. 5, pp. 747-755
Closed Access
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Mimma Rizzo, Andrey Soares, Enrique Grande, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study
Dorothea Strobach, Lisa Haimerl, Hanna Mannell, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 21, pp. 6749-6749
Open Access
Page 1

Scroll to top